ALKERMES | Bruttoavancen På Salg



Gross Profit On Sales Lave om Dato
AbbVie USD 10.71B 458M 2024-12
Acadia Pharmaceuticals USD 237.8M 72.86M 2024-12
ALKERMES USD 146.5M 168.54M 2024-12
Amgen USD 5.97B 781M 2024-12
Biogen USD 1.87B 44.1M 2024-12
BioMarin Pharmaceutical USD 611.17M 53.89M 2024-12
Bristol-Myers Squibb USD 8.18B 947M 2025-03
Eli Lilly USD 10.5B 624.7M 2025-03
Gilead Sciences USD 5.99B 17M 2024-12
Ionis Pharmaceuticals USD 130.15M 92.6M 2025-03
J&J USD 14.6B 816M 2025-03
Malin Corporation EUR 3.8M 2.6M 2020-12
Merck USD 12.77B 849M 2025-03
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
Otsuka Holdings JPY 426.19B 4.1B 2025-03
Pfizer USD 11.12B 987M 2025-03
Regeneron Pharmaceuticals USD 2.56B 659.4M 2025-03
Vertex Pharmaceuticals USD 2.49B 109.3M 2024-12



ALKERMES Bruttoavancen På Salg - Aktuelle værdier, historiske data, prognoser, statistik, diagrammer og økonomisk kalender - May 2025.